The Patient Advisory Board gives this research network the opportunity to get feedback on its research as well as insight in how patients experience having an IMD or hematologic malignancy.
The PAR will support the network with the dissemination of information and communication to the wider patient community and will engage with the appropriate patient communities for disease specific activities and projects.
Since Target-to-B! spans a wide range of diseases several patient organizations are involved in the Patient Advisory Board: Vasculitis Stichting, Spierziekten Nederland, Nationale Vereniging van Sjögren Patiënten, Nationale vereniging voor LUPUS, APS, MCTD en Sclerodermie , Hematon and Netwerk Nederland voor Pemphigus en Pemfigoīd.
Patient representatives are provided with adequate training to be able to fully utilize their individual skills and qualities needed for a fruitful collaboration.
A meeting for patients, family and patient organizations will be organized together with the PAR every 2 years to explain the research and discuss obtained findings crossing disease borders.